Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium
07 February 2019 - 12:00AM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage
biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat,
today announced that the company and its clinical collaborators
will present two poster presentations, including updated
preliminary data from the Phase 2a trial of RX-3117 in advanced
bladder cancer at the 2019 American Society of Clinical Oncology
(ASCO) Genitourinary (GU) Cancers Symposium being held February
14-16, 2019 at the Moscone West Building in San Francisco, CA.
Additional information on the meeting can be
found on the ASCO Genitourinary Cancers Symposium website:
https://gucasym.org/. The full abstracts will be made available
online via https://meetinglibrary.asco.org at 5:00 PM (EST) on
February 11, 2019.
Details of the poster presentations are
as follows:
- Title: Activity of RX-3117, an oral
antimetabolite nucleoside, in subjects with advanced urothelial
cancer: Preliminary results of a phase IIa study.Abstract
Number: 455Poster Board:
K4Session Information: Poster Session B: Prostate
Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and
Adrenal CancersDate/Time: February 15, 12:15
PM-1:45 PM and 5:15 PM-6:15 PM (Pacific Standard
Time)Poster Availability: A copy of the poster
being presented will be available on the Company's website at
https://www.rexahn.com/news-media/posters beginning at 10:00 AM EST
on Friday, February 15, 2019.
- Title: Results of a phase II study
to evaluate the safety and efficacy of RX-0201 in combination with
everolimus in subjects with metastatic renal cell carcinoma
(mRCC).Abstract Number: 646Poster
Board: H19Session Information: Poster
Session C: Renal Cell CancerDate/Time: February
16, 7:00 AM-7:55 AM and 12:30 PM-2:00 PM (Pacific Standard
Time)Poster Availability: A copy of the poster
being presented will be available on the Company's website at
https://www.rexahn.com/news-media/posters beginning at 10:00 AM EST
on Saturday, February 16, 2019.
About
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical
stage biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat.
The Company’s mission is to improve the lives of cancer patients by
developing next-generation cancer therapies that are designed to
maximize efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn’s product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that several
of Rexahn’s product candidates may be effective against multiple
types of cancer, including drug resistant cancers, and
difficult-to-treat cancers and others may augment the effectiveness
of current FDA-approved cancer treatments. The Company has two
oncology product candidates, RX-3117 and RX-5902, in Phase 2
clinical development and additional compounds in preclinical
development, including RX-0301. For more information about the
Company and its oncology programs, please visit www.rexahn.com.
Safe HarborTo the extent any statements made in
this press release deal with information that is not historical,
these are forward-looking statements under the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not
limited to, future operations and products, the path of clinical
trials and development activities, and other statements identified
by words such as “will,” “potential,” “could,” “can,” “believe,”
“intends,” “continue,” “plans,” “expects,” “anticipates,”
“estimates,” “may,” other words of similar meaning or the use of
future dates. Forward-looking statements by their nature address
matters that are, to different degrees, uncertain. Uncertainties
and risks may cause Rexahn’s actual results to be materially
different than those expressed in or implied by Rexahn’s
forward-looking statements. For Rexahn, particular uncertainties
and risks include, among others, understandings and beliefs
regarding the role of certain biological mechanisms and processes
in cancer; drug candidates being in early stages of development,
including clinical development; the ability to initially develop
drug candidates for orphan indications to reduce the time-to-market
and take advantage of certain incentives provided by the U.S. Food
and Drug Administration; the ability to transition from our initial
focus on developing drug candidates for orphan indications to
candidates for more highly prevalent indications; and the expecting
timing of results from our clinical trials. More detailed
information on these and additional factors that could affect
Rexahn’s actual results are described in Rexahn’s filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and subsequent quarterly reports on Form
10-Q. All forward-looking statements in this news release speak
only as of the date of this news release. Rexahn undertakes no
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Media Contact:DGI CommSusan Forman or Laura
Radocaj+1-212-825-3210sforman@dgicomm.comlradocaj@dgicomm.com
Investor Contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2024 to May 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From May 2023 to May 2024